Related by context. All words. (Click for frequent words.) 72 blinded randomized placebo controlled 71 BRIM3 70 BRIM2 70 Phase Ib clinical 70 Carotid Revascularization Endarterectomy vs. 70 relapsed MM 70 Phase Ib II 69 placebo controlled Phase 69 LUX Lung 69 HCV SPRINT 69 Prostate AdenoCarcinoma Treatment 69 placebo controlled clinical 68 multicenter placebo controlled 68 AVADO 68 riociguat 68 AVERROES 68 CARE HF 68 ToGA 68 BCIRG 68 phase Ib 68 DASISION 68 evaluating mipomersen 68 Phase III placebo controlled 68 NSABP B 68 HCV RESPOND 2 67 phase IIIb 67 dosing cohorts 67 galiximab 67 Xelox 67 Enzastaurin 67 PRECiSE 67 multicenter randomized controlled 67 Phase III psoriasis 67 multicenter phase 67 Phase III AFFIRM 67 Phase Ib study 67 RE LY ® 67 phase IIa 67 recurrent malignant glioma 67 RECORD1 67 MAGE A3 ASCI 66 NO# [002] 66 Randomized Double blind 66 multicenter Phase II 66 treatment naive genotype 66 multicentre randomized 66 Prostate Cancer Prevention 66 ExTRACT TIMI 66 CALERIE 66 dose escalation phase 66 TAXUS ATLAS 66 GAMMAGARD 66 Clinical Antipsychotic Trials 66 Edge STudy 66 phase IIb study 66 Randomized Phase II 66 LUMINATE 66 Raloxifene Evaluation MORE 66 Randomized Phase 66 STRIDE PD 66 receptor tyrosine kinase inhibitor 66 CLARITY study 66 SPIRIT FIRST 66 dose escalation clinical 66 RRMS patients 66 Brentuximab Vedotin SGN 66 R# #mg BID 66 SABCS 66 ADVANCE PD 66 Pivotal Phase III 66 registrational Phase 66 Initiated Phase 65 CLL8 65 Phase 1a clinical 65 CATIE AD 65 Phase III Clinical Trials 65 Multicenter Automatic Defibrillator Implantation 65 Pooled Analysis 65 CUSTOM III 65 randomized controlled Phase 65 Oral Fingolimod 65 PERSEUS 65 relapsing remitting MS RRMS 65 Phase IIB 65 randomized multicenter trial 65 AVOREN 65 OPT CHF 65 EOquin TM 65 ongoing Phase 1b 65 TAXUS IV 65 CHAMPION PCI 65 BARI 2D 65 EXPLORE Xa 65 Sapacitabine 65 phase IIa clinical 65 landmark ATHENA 65 multicenter Phase 65 Phase IIIb clinical 65 AIR CF2 65 MERIT ES 65 placebo controlled Phase III 65 Intervention Effectiveness 64 MERLIN TIMI 64 Phase #/#a 64 PreCISe 64 randomized Phase IIb 64 brivanib 64 prospective observational 64 CLARITY TIMI 64 Phase IIb III 64 Randomized Double Blind 64 ENESTnd 64 Teriflunomide 64 dosing cohort 64 Acute Decompensated Heart Failure 64 treatment naïve genotype 64 Phase IIIb 64 multicenter Phase III 64 MGd 64 BOLDER II 64 Tanespimycin 64 Phase 1b clinical trials 64 subanalysis 64 ORAL Sync 64 Tarceva TM 64 Aggressive Reduction 64 IMPACT DCM 64 placebo controlled clinical trials 64 ADMIRE HF 64 acyclovir Lauriad R 64 MADIT II 64 HYVET 64 INSPIRE Trial Phase III 64 REMINYL ® 64 Cholesterol Levels SPARCL 64 AIR CF1 64 PLCO 64 prospective randomized multicenter 64 Chronic Lymphocytic Leukemia CLL 64 multicenter trials 64 ACCORD Lipid 64 mg administered orally 64 YONDELIS 64 ENDEAVOR III 64 NCCTG N# 64 recurrent glioblastoma multiforme 64 COPAXONE R 64 CHARM Added 64 Deforolimus 64 NEVO RES 64 placebo controlled studies 64 EVEREST II 64 Meta analyzes 64 dose cohorts 64 Glucosamine Chondroitin Arthritis 64 PROSTVAC ® 64 AVN# Phase 64 Prostate Lung Colorectal 64 ATAC Arimidex Tamoxifen Alone 64 ONTARGET 64 CYT# potent vascular disrupting 64 Phase III randomized controlled 64 nonrandomized 63 Sorafenib HCC Assessment 63 keloid scarring 63 Dacogen injection 63 fosbretabulin 63 retrospective cohort 63 Afatinib 63 Hepatotoxicity 63 ZD# [001] 63 antiretroviral naïve 63 Traficet EN 63 Truvada tablets 63 Diabetic Nephropathy 63 ORACLE MS 63 pivotal bioequivalence 63 neratinib 63 CAPRIE 63 Pirfenidone 63 Combination REOLYSIN R 63 ZACTIMA 63 randomized Phase III 63 Prospective Randomized 63 number NCT# ClinicalTrials.gov 63 Bayer HealthCare Onyx Pharmaceuticals 63 low dose cytarabine 63 PROSTVAC TM 63 ENDEAVOR II 63 Relapsed Multiple Myeloma 63 evaluable subjects 63 Lenocta 63 Golimumab 63 Intervention Trial GAIT 63 CALGB 63 EURIDIS 63 ENDEAVOR IV 63 BR.# 63 Multicenter 63 REVIVE TA 63 alfa 2a 63 ABCSG 63 Placebo Controlled Trial 63 prucalopride 63 oral FTY# 63 Double Blind Placebo 63 papillary renal cell carcinoma 63 HuMax EGFr 63 crizotinib PF # 63 Phase IIA 63 bevirimat Study 63 ECASS 63 PCI ExTRACT TIMI 63 Randomized Controlled Trials 63 Phase 2b Study 63 sorafenib Nexavar 63 PORxin TM platforms 63 adecatumumab MT# 63 Screening Trial 63 Multiple Ascending Dose 63 placebo controlled trials 63 Active Ulcerative Colitis 63 chronic idiopathic thrombocytopenic purpura 63 prospective observational cohort 63 axitinib 63 MEND CABG 63 Intervention Trial 63 immunomodulatory agents 63 Pafuramidine 63 Sipuleucel T 63 Platelet Inhibition 63 Multicenter Phase 63 Randomized controlled 63 phase 2a 63 Shows Efficacy 63 Randomized Study 63 Subgroup analysis 63 Hormone Refractory Prostate Cancer 63 randomized controlled multicenter 63 brivaracetam 63 randomized Phase 2b 63 teriflunomide 63 ara C 63 oral rivaroxaban 63 multicenter prospective 63 Vertebral Fracture 63 DAPT 63 CRLX# 62 double blinded randomized 62 MIVI III 62 ORAL Solo 62 FOLPI 62 Aflibercept 62 AIR2 Trial 62 PIX# [002] 62 Multicenter Randomized 62 elotuzumab 62 Dose Escalation 62 phase IIb clinical 62 phase IIb trial 62 investigational protease inhibitor 62 Medidur TM FA 62 Clinical Trial Data 62 HORIZONS AMI 62 EOquin TM phase 62 Systemic Sclerosis 62 Hodgkin lymphoma HL 62 vemurafenib 62 genotypic resistance 62 evaluating Xcytrin 62 dose escalation Phase 62 Safinamide 62 AA Amyloidosis 62 Naive Patients 62 EchoCRT 62 trastuzumab emtansine T DM1 62 PSMA ADC 62 LymphoStat B 62 phase Ib clinical 62 Phase #b/#a clinical 62 IIa Clinical Trial 62 huN# DM1 62 Controlled Trial 62 Phase III Pivotal 62 assessing T DM1 62 R roscovitine 62 Pharmacokinetics PK 62 TMC# C# 62 Phase 2b Clinical Trial 62 RE LY 62 ACTIVE W 62 subcutaneous PRO 62 standard chemotherapy regimen 62 Acute Ischemic Stroke 62 Primary endpoints 62 Randomized Clinical Trial 62 Phase Ib IIa 62 Phase III Psoriasis 62 prospective multicentre 62 EORTC 62 Sibutramine Cardiovascular Outcomes 62 patients evaluable 62 Hsp# Inhibitor 62 multicenter randomized Phase 62 Etanercept 62 mITT population 62 Aortic Stenosis 62 alemtuzumab treated 62 Randomised 62 GSK# [001] 62 p# biomarker 62 Randomized Evaluation 62 oral ridaforolimus 62 Randomized Controlled 62 randomized discontinuation trial 62 Pharmacokinetic parameters 62 multicenter randomized clinical 62 alvespimycin 62 confirmatory clinical 62 Clinical Trial Results 62 prospective observational studies 62 Randomized Double Blind Placebo 62 Phase III VISTA 62 HPTN 62 Nymox NX 62 Long Term Efficacy 62 INCB# [003] 62 ThermoDox ® clinical 62 Serious Adverse Events 62 Pharmacokinetic Study 62 Hepatocellular Carcinoma 62 unique alkylating agent 62 APTIVUS 62 sipuleucel T 62 TG MV 62 novel VDA molecule 62 Long Lesion 62 Eculizumab 62 multicenter randomized placebo controlled 62 randomized multicenter Phase III 62 visceral metastases 62 GATTEX TM 62 Motesanib 62 histologically confirmed 62 OvaRex MAb 62 Phase IIIb study 62 Relapsing Multiple Sclerosis 62 TransVax TM 62 Intervention Effectiveness CATIE 62 FOLFIRI chemotherapy 62 Bezielle 62 prospectively defined 62 sunitinib malate 62 Pemetrexed 62 Arimoclomol 62 ASCO Gastrointestinal Cancers Symposium 62 fidaxomicin Phase 3 62 TRITON TIMI 62 efalizumab 62 mertansine 62 Natalizumab 62 bepotastine besilate nasal spray 62 XL# SAR# 62 recurrent glioma 62 Demonstrates Efficacy 62 virological response 61 Delcath Phase III 61 davunetide intranasal AL 61 Hepatocellular Carcinoma HCC 61 TEMSO 61 Heterozygous Familial Hypercholesterolemia 61 randomized controlled clinical trials 61 Clinical Trials Update 61 TASKi2 61 ENGAGE AF TIMI 61 Ranolazine 61 REVIVE Diabetes 61 NATRECOR ® 61 INCB# [001] 61 Prolongs Survival 61 Epratuzumab 61 MADIT CRT trial 61 Placebo Controlled Study 61 blinded randomized 61 neoadjuvant treatment 61 Glufosfamide 61 RSD# oral 61 evaluating REVLIMID 61 Solid Tumors 61 DLTs 61 docetaxel chemotherapy 61 Refractory Angina 61 Betaferon ® 61 RoACTEMRA 61 Tumor Response 61 tramiprosate Alzhemed TM 61 tocilizumab 61 Hedgehog Pathway Inhibitor 61 Cloretazine ® 61 ixabepilone 61 TYGACIL 61 neurologic progression 61 Carotid Endarterectomy 61 BETAS 61 Therapeutic Efficacy 61 IMPACT IMmunotherapy 61 ziprasidone Geodon 61 pomalidomide 61 multicenter multinational 61 Study Evaluating 61 Controlled Study 61 DAPT Study 61 docetaxel Taxotere ® 61 null responder HCV 61 prospective randomized placebo 61 Phase Ib 61 including eniluracil ADH 61 GetGoal Phase III 61 ROCKET AF 61 Tigecycline 61 Pivotal Trial 61 CEQ# 61 randomized controlled trials RCTs 61 Pivotal Phase 61 Carfilzomib 61 Zenvia Phase III 61 tarenflurbil 61 PRE SURGE 61 Cell Lymphoma 61 PROTECT AF 61 multicentre prospective 61 epoetin alpha 61 Newly Diagnosed Multiple Myeloma 61 ONGLYZA ™ 61 Sym# 61 Remission Maintenance 61 Completes Patient Enrollment 61 Rosuvastatin 61 Omacetaxine 61 Ocrelizumab 61 posaconazole 61 MIRCERA 61 monoinfected patients 61 Subtypes 61 viral kinetic 61 preclinical efficacy 61 DermaVir Patch 61 Microalbuminuria 61 DEB# 61 rALLy trial 61 Dasatinib 61 olaparib 61 Liraglutide Effect 61 Septic Shock 61 Quinamed 61 IMPROVE HF 61 dose dose escalation 61 Ozarelix 61 PEGINTRON TM 61 Immunogenicity 61 secondary efficacy endpoints 61 Antitumor Activity 61 intravitreal insert 61 refractory CLL 61 Onrigin 61 ascending dose 61 Folfox 61 Wisconsin Sleep Cohort 61 follicular Non Hodgkin 61 nab paclitaxel 61 Tiotropium 61 MYCAMINE 61 RECIST Response Evaluation Criteria 61 GW# [003] 61 #mg ATC 61 PREVENT IV 61 VADT 61 evaluating tivozanib 61 Targeted Therapy 61 SNT MC# 61 fluvastatin 61 divalproex sodium 61 Phase III randomized 61 NP2 Enkephalin 61 PFO migraine 61 Unstable Angina 61 Medullary Thyroid Cancer 61 Cloretazine 61 Anti Tumor Activity 61 HER2 positive metastatic breast 61 relapsing multiple sclerosis 61 Endovascular Valve Edge 61 Screening Trial DMIST 61 Temsirolimus 61 FAME Study 61 LymphoStat B belimumab 61 myeloproliferative disorders 61 gemcitabine carboplatin 61 nucleotide analogue 61 Alemtuzumab 61 Clinical Outcome 61 CTEPH 61 Cimzia ® certolizumab pegol 61 pharmacokinetic PK 61 TACI Ig 61 Romiplostim 61 baminercept 61 BARACLUDE ® 61 TAXUS VI 61 CAPACITY trials 61 TRANSFORMS 61 prospective nonrandomized 61 Pegylated Liposomal Doxorubicin 61 subgroup analyzes 61 randomized multicenter 61 mg/m2 cohort 61 CALGB # [002] 61 CIMZIA ™ 61 AIM HIGH 61 interferon gamma 1b 61 Investigational Treatment 61 recurrent GBM 61 Prospective Multicenter 61 partial remissions 61 HoFH 61 randomized controlled clinical 61 refractory chronic lymphocytic 61 FOLOTYN ® 61 Genasense ® 61 iPrEx study 61 Trial NLST 61 enzastaurin 61 rapid virologic response 61 Pivotal Clinical Trial 61 HIV HCV coinfected 60 Pharmacokinetic 60 Severe Sepsis 60 GRNVAC1 60 EMPHASIS HF trial 60 Neuroendocrine Tumors 60 APEX AMI trial 60 INxin TM 60 CML CP 60 thalidomide Thalomid 60 BEXXAR Therapeutic Regimen 60 Clinical Efficacy 60 Hydroxyurea 60 ZOLINZA 60 samalizumab 60 Dose Ranging Study 60 Oral Calcitonin 60 dirucotide MBP# 60 Phase 1b trial 60 trastuzumab DM1 T DM1 60 Phase IIa trials 60 UPLYSO 60 pharmacokinetic PK study 60 Angiographic 60 Rigel R# 60 Virologic 60 cilengitide 60 STEP BD 60 controlled multicenter Phase 60 myelofibrosis polycythemia vera 60 dose cohort 60 Ovarian PLCO Cancer 60 paclitaxel Taxol R 60 forodesine 60 Randomized Trials 60 ATACAND 60 SCD HeFT 60 rFVIIa 60 Renal Cell Carcinoma RCC 60 relapsed myeloma 60 Initiate Phase 60 Exelixis XL# 60 aripiprazole Abilify 60 KRAS status 60 HDAC Inhibitor 60 Leukemias 60 dosage regimens 60 TRA 2P 60 phase III ACCLAIM 60 Ophena TM 60 Blind Placebo Controlled Trial 60 weekly subcutaneous injections 60 cinacalcet 60 CANCIDAS 60 ORENCIA R 60 #th Annual Interscience 60 AZILECT R 60 evaluable patients 60 Demonstrate Significant 60 ORENCIA ® 60 #rd Annual CTRC 60 Targretin capsules 60 randomized discontinuation 60 ILLUMINATE 60 SYMMETRY trial 60 basal bolus regimen 60 Amrubicin 60 LibiGel Phase III 60 TORISEL 60 CD# CEA 60 double blinded placebo 60 Nilotinib 60 #F FDG PET 60 heavily pretreated patients 60 Pertuzumab 60 NCT# ClinicalTrials.gov 60 Follicular Lymphoma 60 rilonacept 60 flavopiridol 60 bevacizumab Avastin 60 Meets Primary Endpoint 60 ASCO GI 60 PegIFN RBV 60 cediranib 60 Placebo Controlled 60 PROactive study 60 NCIC CTG 60 JAK Inhibitor 60 PKC# 60 II Clinical Trial 60 Fondaparinux 60 leukemia AML 60 HCV Protease Inhibitor 60 Dacogen decitabine 60 Diabetic Macular Edema 60 Stent Restenosis 60 HSCT 60 Pivotal Trials 60 HORIZONS AMI trial 60 Clinical Outcomes Utilizing Revascularization 60 ganetespib 60 QLT# 60 TYKERB 60 biliary tract cancer 60 Phase III multicenter 60 ISTODAX ® 60 nonsmall cell lung cancer 60 Vidaza azacitidine 60 Patients Receiving 60 phase IIb 60 quadrivalent HPV vaccine 60 Shows Promise Against 60 relapsed ALL 60 ancrod 60 prospectively enrolled 60 Phase 2b kidney transplant 60 Lomitapide 60 budesonide foam 60 ritonavir boosted 60 trials RCTs 60 Parathyroid Hormone 60 Immunosuppression 60 cMET 60 weekly intravenous infusions 60 Elagolix 60 CLORETAZINE TM VNP#M 60 GATTEX ™ 60 metastatic hormone refractory 60 ENDEAVOR clinical 60 RhuDex 60 Thrombolysis 60 Certolizumab 60 PEG IFN 60 Successfully Completes Phase 60 Myelodysplastic Syndrome MDS 60 Azacitidine 60 PRIMO CABG2 60 Pharmacodynamics 60 eculizumab therapy 60 vismodegib 60 Chronic Myeloid Leukemia 60 Response Evaluation Criteria 60 pharmacodynamic parameters 60 trastuzumab Herceptin ® 60 G#DT 60 recurrent metastatic 60 CALGB # [001] 60 Phase 2a 60 dyskinesia PD LID 60 solithromycin 60 Telbivudine 60 cancer mCRC 60 placebo controlled randomized 60 Decitabine 60 relapsed MCL 60 Dalbavancin 60 Plicera 60 midstage clinical 60 Romidepsin 60 Digital Mammographic Imaging 60 BEZ# 60 EGS# 60 Dose Ranging 60 Xanafide 60 Advanced Melanoma 60 Raptiva ® 60 tolvaptan 60 PEGylated interferon beta 1a 60 Vaccine Protects Against 60 Aplidin R 60 WHIMS 60 Triapine R 60 PROMACTA 60 Spectrum Pharmaceuticals Announces 60 Degarelix 60 lenalidomide Revlimid R 60 Dialysis Outcomes 60 Potent Antiviral Activity 60 Secondary efficacy endpoints 60 TORISEL TM 60 MVax R 60 lintuzumab SGN 60 alicaforsen enema 60 PROSTVAC VF 60 Sprycel dasatinib 60 Protease Inhibitor 60 mycophenolate mofetil 60 Phase 1b 60 Risk Stratification 60 SPARCL 60 Adjuvant Chemotherapy 60 Inflammatory Markers 60 WHEL 60 Phase III Clinical Trial 60 Late Breaker 60 Prednisone Against Refractory 60 romiplostim 60 Cardiotoxicity 60 Health Initiative Observational 60 biologic DMARD 60 farletuzumab 60 CIMZIA TM 60 OLYMPIA registry 60 ARIXTRA R 60 polyarticular 60 EINSTEIN DVT 60 PEG INTRON R 60 Adjuvant Treatment 60 intradermal injections 60 Daclizumab 60 Randomized Phase III 60 stage IIIB 60 Confirmatory Phase 60 Kahalalide F 60 Valsartan 60 Diamyd Medical Diamyd 60 Genotypes 59 phase III isavuconazole 59 Phase III ThermoDox 59 HGS ETR2 59 Phase 2a trial 59 HCV Genotype 59 HBV infections 59 Non Alcoholic Steatohepatitis 59 morphometric vertebral fractures 59 biochemical relapse 59 Hypertensive adverse reactions 59 Phase 1b clinical 59 Efficacy Results 59 canakinumab 59 ICAAC IDSA 59 Plaque Psoriasis 59 Talabostat 59 DIRECT Trial 59 Non inferiority 59 pharmacokinetics PK 59 rALLy clinical trial 59 ENDEAVOR IV clinical 59 sarcoma melanoma 59 CIMZIA TM certolizumab pegol 59 Venous Thromboembolism 59 DDP# 59 Preclinical Data 59 CUSTOM II 59 Solorel 59 randomized multicentre 59 APEX PD 59 Metastatic Colorectal Cancer 59 Antitumor 59 dose regimens 59 Arch Surg 59 Tesmilifene 59 Phase IIb Clinical Trial 59 chemotherapeutic regimen 59 Myocardial Infarction Study 59 #mg QD [002] 59 Mycophenolate Mofetil 59 Blinatumomab 59 Fingolimod 59 randomized blinded 59 Meta Analysis 59 Clostridium difficile Infection 59 Bare Metal Stent 59 observational cohort study 59 Investigational Compound 59 fidaxomicin Phase 59 Cohort Study MACS 59 Tolvaptan 59 PRoFESS 59 underwent surgical resection 59 BEXXAR therapeutic regimen 59 Antiviral Activity 59 IFN α 59 Pharmacodynamic 59 Cethromycin 59 ELACYT 59 evaluating Vectibix 59 COMFORT II 59 SPIRIT IV 59 ALT flares 59 Relapsing Remitting Multiple Sclerosis 59 visilizumab 59 desvenlafaxine succinate 59 Protease Inhibitors 59 Apixaban 59 icatibant 59 Glatiramer Acetate 59 NEUGENE 59 First Patient Dosed 59 heFH 59 Virulizin ® 59 OncoVex 59 Autologous Stem Cell Transplantation 59 BIBW 59 antiviral efficacy 59 NVA# 59 glatiramer acetate 59 Phase #b/#a 59 SIMPADICO 59 PANVAC VF 59 Preclinical Efficacy 59 PROTEGE 59 AML MDS 59 ARCOXIA 59 Double Blind Randomized 59 evaluating satraplatin plus 59 ASCO GU 59 GOUT 59 SORT OUT III 59 lumiliximab 59 ACCEDE 59 multicentre 59 Chronic Lymphocytic Leukemia 59 Liver Metastases 59 Second Pivotal Phase 59 Vitaxin 59 paclitaxel poliglumex 59 abiraterone acetate 59 interferon beta 1b 59 bendamustine 59 Betaferon R 59 SWOG 59 NLX P# 59 Phase Ib Clinical Trial 59 selenium supplementation 59 Zemplar Capsules 59 SNT-MC#/idebenone 59 See CLINICAL PHARMACOLOGY 59 NovoTTF 59 SPIRIT III 59 elacytarabine 59 Valortim R 59 Fludarabine 59 Phase IIb Trial 59 ALLHAT 59 docetaxel Taxotere R 59 iPrEx 59 meta analysis pooling 59 EndoTAG TM -1 59 Saforis 59 duplex ultrasonography 59 EQUIP OB 59 Anticancer Drugs 59 Treated Patients 59 Cancer Incidence Mortality 59 Methylnaltrexone 59 Phase 2a Trial 59 multicenter clinical 59 Val HeFT 59 Stenting Trial CREST 59 LHON 59 MenACWY 59 Tipranavir 59 colesevelam HCl 59 substudy 59 multicenter randomized 59 RIO Lipids 59 mg q#h 59 sunitinib Sutent 59 huC# DM4 59 demonstrated antitumor activity 59 Metastatic Melanoma 59 cisplatin gemcitabine 59 metastatic castration resistant 59 PD LID 59 afatinib 59 CLL SLL 59 MCSP respectively 59 BRAF inhibitor 59 Eltrombopag 59 atazanavir ritonavir 59 prospective randomized controlled 59 IBS C 59 Multicenter AIDS 59 ponatinib 59 Alagebrium 59 By JENNIFER LEARN 59 Pre RELAX AHF 59 Allovectin 7 ® 59 VFEND 59 BiTE antibodies targeting 59 Treatment Resistant 59 events SAEs 59 Cloretazine R VNP#M 59 PARTNER Trial 59 undetectable HBV DNA 59 bazedoxifene conjugated estrogens 59 Patient Outcomes 59 ANCHOR trial 59 metastatic malignant 59 Adverse Event 59 ONCONASE R 59 COU AA 59 paclitaxel cisplatin 59 flurpiridaz F 59 ICON7 59 Anti CD# Antibody 59 GISSI 59 evaluating Actimmune 59 adjuvant endocrine therapy 59 Nasdaq ONXX today 59 Preclinical Study 59 Denufosol 59 NOMID 59 telaprevir dosing 59 Matrix Phase 2b 59 haematologic 59 bortezomib refractory 59 resectable pancreatic cancer 59 anastrazole 59 CHAMPION PLATFORM 59 mg BID dose 59 Mg Usa 59 Confirms Efficacy 59 registrational clinical 59 ascending doses 59 Topline Results 59 metastatic HRPC 59 CIMZIA R 59 Colorectal Cancer Patients 59 Tyrosine Kinase Inhibitor 59 reduce serum phosphate 59 Phase IIb trials 59 #mg/m# [002] 59 VELCADE melphalan 59 Fulvestrant 59 Dr. Kandzari 59 Polyp Prevention Trial 59 targeting miR 59 hypercholesterolemic patients 59 relapsed refractory multiple myeloma 59 Castration Resistant Prostate Cancer 59 tipifarnib 59 Etravirine 59 FASEB J. 59 decompensated liver disease 59 CCR5 mAb 59 systemic Phase 1b 59 q8h 59 IL# PE#QQR 59 Perifosine KRX 59 designated HVTN 59 cynomolgus macaques 59 Soft Tissue Sarcoma 59 efavirenz EFV 59 Phase III Trial 59 CCyR 59 Cardiac Biomarkers 59 familial amyloidotic polyneuropathy FAP 59 NATRECOR R 59 SUCCEED trial 59 abstracts summarizing 59 ACTEMRA 59 Myelodysplastic Syndromes 59 AZT zidovudine Retrovir 59 TEMODAL 59 depsipeptide 59 Left Ventricular Dysfunction 59 recurrent metastatic ovarian cancer 59 Regimens 59 CERVARIX 59 ABSORB trial 59 CTAP# Capsules 59 Demonstrates Significant 59 recurrent NSCLC